Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is -9.67% lower on its value in year-to-date trading and has touched a low of $1.76 and a high of $6.48 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The PHIO stock was last observed hovering at around $2.37 in the last trading session, with the day’s gains setting it 0.06% off its average median price target of $4.00 for the next 12 months. It is also 39.25% off the consensus price target high of $4.00 offered by 1 analysts, but current levels are 39.25% higher than the price target low of $4.00 for the same period.
Currently trading at $2.43, the stock is -2.47% and -14.50% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.43 million and changing 2.53% at the moment leaves the stock -5.92% off its SMA200. PHIO registered 33.88% gain for a year compared to 6-month gain of 17.96%. The firm has a 50-day simple moving average (SMA 50) of $2.6726 and a 200-day simple moving average (SMA200) of $2.6951.
The stock witnessed a -6.18% loss in the last 1 month and extending the period to 3 months gives it a -20.59%, and is 3.40% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.91% over the week and 6.90% over the month.
Distance from 52-week low is 38.07% and -62.50% from its 52-week high.
Phio Pharmaceuticals Corp. (PHIO) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Phio Pharmaceuticals Corp. (PHIO) is a “Buy”. 1 analysts offering their recommendations for the stock, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Phio Pharmaceuticals Corp. is expected to release its quarterly report on 08/17/2021 and quarterly earnings per share for the current quarter are estimated at $0.The EPS is expected to grow by 90.10% this year.
Phio Pharmaceuticals Corp. (PHIO) Top Institutional Holders
17 institutions hold shares in Phio Pharmaceuticals Corp. (PHIO), with 165.36k shares held by insiders accounting for 1.22% while institutional investors hold 8.84% of the company’s shares. The shares outstanding are 13.53M, and float is at 13.49M with Short Float at 4.66%. Institutions hold 8.73% of the Float.
The top institutional shareholder in the company is Gsa Capital Partners Llp with over 0.1 million shares valued at $0.27 million. The investor’s holdings represent 0.75% of the PHIO Shares outstanding. As of Dec 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 73490.0 shares valued at $0.2 million to account for 0.54% of the shares outstanding. The other top investors are Two Sigma Advisers, LP which holds 67700.0 shares representing 0.50% and valued at over $0.18 million, while Dimensional Fund Advisors LP holds 0.19% of the shares totaling 25177.0 with a market value of $67726.0.
Phio Pharmaceuticals Corp. (PHIO) Insider Activity
A total of 0 insider transactions have happened at Phio Pharmaceuticals Corp. (PHIO) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider purchase by Dispersyn Gerrit, the company’s President & CEO. SEC filings show that Dispersyn Gerrit bought 1,953 shares of the company’s common stock on Mar 04 at a price of $2.56 per share for a total of $5000.0. Following the purchase, the insider now owns 89281.0 shares.
Phio Pharmaceuticals Corp. disclosed in a document filed with the SEC on Mar 03 that Ferrara Robert L (Director) bought a total of 682 shares of the company’s common stock. The trade occurred on Mar 03 and was made at $3.15 per share for $2148.0. Following the transaction, the insider now directly holds 13000.0 shares of the PHIO stock.
Still, SEC filings show that on Mar 03, Dispersyn Gerrit (President & CEO) acquired 2,500 shares at an average price of $3.03 for $7575.0. The insider now directly holds 87,328 shares of Phio Pharmaceuticals Corp. (PHIO).